Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, Yang J, Hu Y, Chen Y, Lin L, Hao J, Li J, Chen J, Li M, Wu Q, Peters C, Zhou Q, Li J, Liang Y, Wang X, Han B, Ma M, Kabelitz D, Xu K, Tu W, Wu Y, Yin Z.
Xu Y, et al. Among authors: zhou q.
Cell Mol Immunol. 2021 Feb;18(2):427-439. doi: 10.1038/s41423-020-0515-7. Epub 2020 Sep 16.
Cell Mol Immunol. 2021.
PMID: 32939032
Free PMC article.